Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 10/20 | 0.53 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.51 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.51 |
| ▸ | DPP7 | Q9UHL4 | 7/20 | 0.51 |
| ▸ | DPP4 | P27487 | 4/20 | 0.51 |
| ▸ | SLC15A1 | P46059 | 1/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28295881 | 1.00 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL2200199 | 1.00 | NOD1 (0.53) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31433224 | 0.94 | NOD1 (0.55) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31433288 | 0.93 | NOD1 (0.48) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL31433194 | 0.92 | NOD1 (0.47) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29382412 | 0.89 | NOD1 (0.55) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL2850058 | 0.89 | DPP7 (0.58) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL29376792 | 0.89 | DPP7 (0.58) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL8495657 | 0.88 | DPP4 (0.54) | NOD1DPP8DPP9DPP7DPP4 | |
| SCHEMBL8497101 | 0.87 | DPP7 (0.57) | NOD1DPP8DPP9DPP7DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715637-A | Glucokinase activators and its application method | 百时美施贵宝公司 | 2019-05-03 | — | — | CN | disclosed |